[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342652-105":59,"doc-detail-342652-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","aberrantly-glycosylated-glut1-as-a-poor-prognosis-marker-in-aggressive-bladder-cancer","Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer","","Muscle-invasive bladder cancer (MIBC) persists as a major health challenge because conventional therapies often fail and tumors show substantial molecular heterogeneity, limiting new targeted treatments. Glycoproteomics and bioinformatics data suggest GLUT1 as a targetable biomarker due to higher expression in tumors than in healthy tissue. This study analyzes GLUT1 expression and glycosylation patterns across human bladder tumors, linking increased GLUT1, specific glycosylation features, and reduced overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/aberrantly-glycosylated-glut1-as-a-poor-prognosis-marker-in-aggressive-bladder-cancer/342652/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/aberrantly-glycosylated-glut1-as-a-poor-prognosis-marker-in-aggressive-bladder-cancer/342652.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is GLUT1 investigated in muscle-invasive bladder cancer?","Question",{"text":112,"@type":113},"GLUT1 was identified from glycoproteomics and bioinformatics as a potential biomarker because its expression is increased in tumors compared with healthy tissue. The study further evaluates whether GLUT1 glycosylation patterns add cancer specificity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does GLUT1 expression relate to cancer severity and patient outcomes?",{"text":117,"@type":113},"Immunohistochemistry shows GLUT1 expression increases with lesion severity and extends to metastasis, while remaining undetectable in healthy urothelium. GLUT1 is also associated with reduced overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What specific GLUT1 glycosylation findings support its prognostic value?",{"text":121,"@type":113},"Reanalysis of nanoLC-EThcD-MS/MS data targeting immature O-glycosylation indicates GLUT1 carries short glycosylation linked to invasive disease. Glycosite mapping reveals patient heterogeneity but also shared glycopatterns that may support targeted therapeutic approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342652,1790160586,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Communication  \nAberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer  \nEduardo Ferreira 1,2, Dylan Ferreira 1,2,3,4,5, Marta Relvas-Santos 1,2,3,4,5,6, Rui Freitas 1,2,3,4,5,  \nJanine Soares 1,2,3, Rita Azevedo 7, Luís Pedro Afonso 1,2, Luís Lima 1,2, Beatriz Santos 1,2, Martina Gonçalves 1,2, André M. N. Silva 3,6,8, Lúcio Lara Santos 1,2,8,9, Andreia Peixoto 1,2,4,5, * and José Alexandre Ferreira 1,2,3,8, *  \nCitation: Ferreira, E.; Ferreira, D.; Relvas-Santos, M.; Freitas, R.; Soares, J.; Azevedo, R.; Afonso, L.P.; Lima, L.; Santos, B.; Gonçalves, M.; et al. Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer. Int. J. Mol. Sci. 2024, 25, 3462. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25063462  \nAcademic Editor: Alain Couvineau  \nReceived: 12 February 2024  \nRevised: 7 March 2024  \nAccepted: 12 March 2024  \nPublished: 19 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Experimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP), 4200-072 Porto, Portugal; [i37310@ipoporto.min-saude.pt](i37310@ipoporto.min-saude.pt) (E.F.); [i38795@ipoporto.min-saude.pt](i38795@ipoporto.min-saude.pt) (D.F.); [marta.relvas.santos@ipoporto.min-saude.pt](marta.relvas.santos@ipoporto.min-saude.pt) (M.R.-S.); [rui.freitas@ipoporto.min-saude.pt](rui.freitas@ipoporto.min-saude.pt) (R.F.); [janinepaivasoares@gmail.com](janinepaivasoares@gmail.com) (J.S.); [luis.afonso@ipoporto.min-saude.pt](luis.afonso@ipoporto.min-saude.pt) (L.P.A.); [luis.carlos.lima@ipoporto.min-saude.pt](luis.carlos.lima@ipoporto.min-saude.pt) (L.L.); [beatriz.santos@ipoporto.min-saude.pt](beatriz.santos@ipoporto.min-saude.pt) (B.S.); [martina.goncalves@ipoporto.min-saude.pt](martina.goncalves@ipoporto.min-saude.pt) (M.G.); [lucio.santos@ipoporto.min-saude.pt](lucio.santos@ipoporto.min-saude.pt) (L.L.S.)  \n2 RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal  \n3 ICBAS—Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal; [andre.silva@fc.up.pt](andre.silva@fc.up.pt)  \n4 i3S—Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal  \n5 INEB—Institute for Biomedical Engineering, University of Porto, 4200-135 Porto, Portugal  \n6 REQUIMTE-LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal  \n7 Institut Pasteur, Proteomics Core Facility, MSBio UtechS, 75015 Paris, France; [rita.pereir@hotmail.com](rita.pereir@hotmail.com)  \n[8](8 GlycoMatters Biotech)[ GlycoMatters Biotech](8 GlycoMatters Biotech), [4500-162 Espinho](4500-162 Espinho), [Portugal](Portugal)  \n9 Department of Surgical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal  \n* Correspondence: [andreia.peixoto@ipoporto.min-saude.pt](andreia.peixoto@ipoporto.min-saude.pt) (A.P.); [jose.a.ferreira@ipoporto.min-saude.pt](jose.a.ferreira@ipoporto.min-saude.pt)[ ](jose.a.ferreira@ipoporto.min-saude.pt)(J.A.F.); Tel.: +351-225084000 (ext. 5111) (A.P. & J.A.F.)  \nAbstract: Muscle-invasive bladder cancer (MIBC) remains a pressing health concern due to conventional treatment failure and significant molecular heterogeneity, hampering the development of novel targeted therapeutics. In our quest for novel targetable markers, recent glycoproteomicsand bioinformatics data have pinpointed (glucose transporter 1) GLUT1 as a potential biomarker due to its increased expressio","cbCaitpY21OAkiVU","https://ap.wps.com/l/cbCaitpY21OAkiVU","pdf",3081098,14,"English","# Abstract\n# Introduction","[{\"question\":\"Why is GLUT1 investigated in muscle-invasive bladder cancer?\",\"answer\":\"GLUT1 was identified from glycoproteomics and bioinformatics as a potential biomarker because its expression is increased in tumors compared with healthy tissue. The study further evaluates whether GLUT1 glycosylation patterns add cancer specificity.\"},{\"question\":\"How does GLUT1 expression relate to cancer severity and patient outcomes?\",\"answer\":\"Immunohistochemistry shows GLUT1 expression increases with lesion severity and extends to metastasis, while remaining undetectable in healthy urothelium. GLUT1 is also associated with reduced overall survival.\"},{\"question\":\"What specific GLUT1 glycosylation findings support its prognostic value?\",\"answer\":\"Reanalysis of nanoLC-EThcD-MS/MS data targeting immature O-glycosylation indicates GLUT1 carries short glycosylation linked to invasive disease. Glycosite mapping reveals patient heterogeneity but also shared glycopatterns that may support targeted therapeutic approaches.\"}]","Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer | PDF",1790047550,35]